Published in Int J Radiat Oncol Biol Phys on April 10, 2012
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 0.84
Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study. Radiat Oncol (2014) 0.80
Liver regeneration following repeat SBRT. J Gastrointest Oncol (2015) 0.78
Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic contrast-enhanced MRI. PLoS One (2013) 0.77
Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J (2015) 0.75
Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg (2012) 0.75
Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother (2015) 0.75
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.14
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.91
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol (2010) 1.55
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol (2006) 1.53
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol (2007) 1.49
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol (2011) 1.47
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys (2008) 1.09
A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments. Int J Radiat Oncol Biol Phys (2009) 1.09
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol (2009) 1.07
Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271). Int J Radiat Oncol Biol Phys (2008) 1.07
Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys (2003) 1.05
Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park) (2004) 1.05
On the impact of longitudinal breathing motion randomness for tomotherapy delivery. Phys Med Biol (2008) 1.03
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2010) 1.02
Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol (2002) 0.99
Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys (2011) 0.99
Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-based Study Evaluating Health Care Disparities in the United States According to Insurance Status. Am J Clin Oncol (2016) 0.97
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2012) 0.96
Atom Michelson interferometer on a chip using a Bose-Einstein condensate. Phys Rev Lett (2005) 0.95
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol (2008) 0.94
Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg (2006) 0.92
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2007) 0.92
On the making of sharp longitudinal dose profiles with helical tomotherapy. Phys Med Biol (2007) 0.91
Feasibility and sensitivity study of helical tomotherapy for dose painting plans. Acta Oncol (2010) 0.88
Dose as a function of liver volume and planning target volume in helical tomotherapy, intensity-modulated radiation therapy-based stereotactic body radiation therapy for hepatic metastasis. Int J Radiat Oncol Biol Phys (2006) 0.88
Stereotactic body radiation therapy. Curr Probl Cancer (2005) 0.87
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol (2014) 0.86
Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncol (2011) 0.86
The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. Int J Radiat Oncol Biol Phys (2002) 0.86
The subventricular zone neural progenitor cell hypothesis in glioblastoma: epiphany, Trojan Horse, or Cheshire fact? Int J Radiat Oncol Biol Phys (2013) 0.85
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol (2013) 0.85
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2008) 0.85
A phantom model demonstration of tomotherapy dose painting delivery, including managed respiratory motion without motion management. Phys Med Biol (2010) 0.84
Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta Oncol (2010) 0.84
Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Med Dosim (2002) 0.83
Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli. Clin Cancer Res (2010) 0.83
Motion management and image guidance for thoracic tumor radiotherapy: clinical treatment programs. Front Radiat Ther Oncol (2011) 0.82
High-dose MVCT image guidance for stereotactic body radiation therapy. Med Phys (2012) 0.82
Lung cancer: a model for implementing stereotactic body radiation therapy into practice. Front Radiat Ther Oncol (2007) 0.82
Esophageal cancer patients undergoing external beam radiation after placement of self-expandable metal stents: is there a risk of radiation dose enhancement? Gastrointest Endosc (2011) 0.81
Radiation therapy for liver metastases. Semin Radiat Oncol (2011) 0.80
High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials. Clin Lung Cancer (2008) 0.79
Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys (2013) 0.79
Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys (2012) 0.79
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol (2015) 0.79
Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer J (2016) 0.78
Dosimetric and deformation effects of image-guided interventions during stereotactic body radiation therapy of the prostate using an endorectal balloon. Med Phys (2012) 0.78
The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol (2006) 0.78
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys (2010) 0.78
A detailed evaluation of TomoDirect 3DCRT planning for whole-breast radiation therapy. Med Dosim (2013) 0.77
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2010) 0.77
Is Less, More? The Evolving Role of Radiation Therapy for Brain Metastases. Int J Radiat Oncol Biol Phys (2015) 0.76
The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. J Appl Clin Med Phys (2006) 0.76
Triple modality (neoadjuvant chemoradiotherapy followed by surgical resection): is it better than definitive chemoradiation therapy in cancer of the thoracic esophagus? Int J Radiat Oncol Biol Phys (2002) 0.75
Selective internal radiotherapy in metastatic esophageal adenocarcinoma. Gastrointest Cancer Res (2011) 0.75
The emperor's new isodose curves. Med Phys (2003) 0.75
A technique for stereotactic radiosurgery treatment planning with helical tomotherapy. Med Dosim (2011) 0.75
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. Am J Clin Oncol (2017) 0.75
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. J Med Imaging Radiat Oncol (2014) 0.75
Stereotactic body radiation therapy: a new paradigm in radiotherapy management of cancer. J Am Coll Radiol (2008) 0.75
Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapy. Oncology (Williston Park) (2014) 0.75
Toward a unified target theory in oncology. Future Oncol (2006) 0.75
The effect of high-dose-rate brachytherapy dwell sequence on cell survival. Int J Radiat Oncol Biol Phys (2002) 0.75